Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (9)

2016

  1. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro

    Journal of Endocrinology, Vol. 231, Núm. 2, pp. 135-145

2006

  1. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial

    Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326

2004

  1. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA)

    European Journal of Endocrinology, Vol. 151, Núm. 4, pp. 439-446

2003

  1. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage

    Clinical Endocrinology, Vol. 58, Núm. 4, pp. 471-481

1996

  1. Carcinoma medular de tiroides. Factores pronósticos

    Revista Clinica Espanola, Vol. 196, Núm. 2, pp. 92-98

1991

  1. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide

    Journal of Endocrinological Investigation, Vol. 14, Núm. 1, pp. 17-23

  2. PRUEBAS DE TRATAMIENTO AGUDO CON SMS 201-995 EN ACROMEGALICOS

    Revista Clinica Espanola, Vol. 189, Núm. 3, pp. 110-114

  3. Results of trans-sphenoidal surgery for the treatment of acromegaly

    Revista clínica española, Vol. 188, Núm. 2, pp. 76-80

1988

  1. Response of growth hormone to acute infusion of growth hormone releasing factor (1-29) in patients with acromegaly. Comparison of baseline levels of growth hormone with levels obtained with somatostatin of prolonged action

    Revista Clinica Espanola, Vol. 182, Núm. 4, pp. 187-191